Author: Annovis Bio Inc.

Posted Date:

May 7, 2026

Annovis CEO to Present on Multi-Protein Model of Alzheimer’s Disease at Fierce Biotech Week 2026

Annovis Bio Inc.

May 7, 2026
Annovis Publishes Phase 2/3 Alzheimer’s Trial Results in Nature Portfolio

Annovis Bio Inc.

May 6, 2026
Annovis Publishes Phase 2/3 Alzheimer’s Trial Results in Nature Portfolio

Annovis Bio Inc.

April 29, 2026
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants

Annovis Bio Inc.

April 9, 2026
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

Annovis Bio Inc.

April 2, 2026
Annovis Publishes Historical Review of Buntanetap in The Scientist

Annovis Bio Inc.

March 31, 2026
Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson’s Disease Study

Annovis Bio Inc.

March 19, 2026
Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results

Annovis Bio Inc.

March 16, 2026
Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference

Annovis Bio Inc.

March 3, 2026
Annovis Secures DSMB Approval to Advance Pivotal Phase 3 Trial of Buntanetap in Alzheimer’s Disease

Annovis Bio Inc.

February 12, 2026